<DOC>
	<DOCNO>NCT00131664</DOCNO>
	<brief_summary>The incidence type 2 diabetes increase . According recent Canadian Diabetes Association guideline glucose control , base A1C measurement , need achieve within 6-12 month period time initial diagnosis type 2 diabetes . The guideline use antihyperglycemic agent identify potential benefit sub-maximal oral combination therapy order achieve rapid improved glycemic control compare high dose monotherapy . Furthermore , many patient prolonged oral antihyperglycemic monotherapy start combination therapy may achieve require target glycemic control . Indeed early initiation combination therapy may necessary achieve maintain glycemic target progressive deterioration pancreatic β cell function glycemic control .</brief_summary>
	<brief_title>Avandia™ + Amaryl™ Avandamet™ Compared With Metformin ( AVALANCHE™ Study )</brief_title>
	<detailed_description>AvandametTM combine two oral antihyperglycemic agent , rosiglitazone maleate metformin hydrochloride , different complementary mechanism action improve glycemic control reduce circulate insulin level patient type 2 diabetes . AvandiaTM AmarylTM combine two antidiabetic agent , rosiglitazone maleate glimepiride . Glimepiride effective antihyperglycemic agent low incidence hypoglycemia , symptomatic hypoglycemia , severe hypoglycemia , confirm hypoglycemia . Subjects study inadequately control diet , exercise submaximal dose metformin sulfonylurea ( SU ) randomize either combination metformin plus rosiglitazone ( AvandametTM ) combination AvandiaTM + AmarylTM Metformin monotherapy arm . As per Canadian Diabetes Association ( CDA ) guideline , fast plasma glucose A1C 7 ( mmol/L / percent ) less throughout study . If subject achieve target either AvandametTM AvandiaTM AmarylTM Metformin up-titrated effort reach CDA recommend target . This study attempt demonstrate either combination arm rosiglitazone plus metformin ( AvandametTM ) combination arm AvandiaTM + AmarylTM provide great glycemic control avoid side-effects associate use maximal dose metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>1 . Type 2 diabetes patient 2 . 18 75 year old 3 . Type 2 diabetes mellitus ( DM ) drug naïve submaximal oral monotherapy &lt; 3 year 4 . A1C criterion screen : 1 . 7.110 % drug naïve patient failure diet control lifestyle modification 2 . 7.1 9 % single therapy ( e.g . 10 mg Glyburide 4 mg Amaryl™ 1000mg Metformin ) start 2 week washout . During wash follow do : ) diet life style modification ii ) Angiotensin convert enzyme inhibitor ( ACE ) , aspirin ( 80 mg ) , statin appropriate 5 . Signed informed consent 1 . Type 1 diabetes 2 . Subjects currently treat insulin 3 . Subject treat previous 3 month thiazolidinedione ( TZD ) 4 . Evidence clinically significant concomitant illness control medication and/or may limit participation study judge investigator 5 . Subjects hypersensitivity component study drug 6 . Participation clinical trial and/or intake investigational drug within 30 day prior screen . 7 . Pregnant nursing female 8 . Females childbearing potential adequate birth control 9 . Liver enzyme ( Alanine Aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ) 10 . Renal impairment : serum creatinine ≥ 136umol/L ( male ) ≥ 124 umol/L ( female ) 11 . Congestive Heart Failure ( CHF class III/IV ) 12 . Weight &gt; 160 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>